AMRA Medical

04/11/2025

Explore AMRA’s Latest Insights In Liver Disease Research @ AASLD 2025!

November is upon us and that means it is once again time for AASLD’s The Liver Meeting®! This year, the AMRA team is thrilled to be in attendance to share updates on Saturday, November 8th from three studies using our MRI-based muscle assessment biomarkers in MASH cirrhosis research, done in collaboration with our colleagues at Virginia Commonwealth University (VCU), Indiana University (IU), and Linköping University (LiU):

➡️ “Reduced Fat and Muscle Volumes in Decompensated Cirrhosis: A Whole-Body MRI Study” | Poster #2470

➡️ “Muscle Composition Matters: MRI-Based Myosteatosis Strongly Correlates with Physical Function in Cirrhosis” | Poster #2384

➡️ “Muscle quality, defined by low muscle volume and muscle fat index on MRI, is worse in decompensated NASH cirrhosis, but not in compensated MASH cirrhosis” | Poster #2642 | Presented by Dr. Samala, IU

These poster presentations highlight AMRA’s evaluation of muscle wasting in MASH and cirrhosis. Using our muscle assessment score (MAsS) biomarkers, the studies show that the prevalence of the adverse muscle composition phenotype, defined by low muscle volume z-score and high muscle fat infiltration, increases drastically in decompensated MASH cirrhosis.

In addition, strong correlations between the MAsS biomarkers and standard physical function tests in patients with decompensated cirrhosis is demonstrated. Collectively, these studies underscore the value of AMRA’s MRI-based MAsS biomarkers for use in evaluating muscle wasting in liver disease studies.

If you’ll be in DC next week, reach out to any of our team members - Mikael Forsgren, Maria Rydfjord, or Conrad Maurais, - who will be in attendance at The Liver Meeting®. Or contact info@amramedical.com to set up some time to discuss how AMRA’s MRI-based fat and muscle biomarkers can help you transform your trials in MASH, cirrhosis, and beyond.

We can’t wait to see you in DC!

30/10/2025

Connect With AMRA at MYO-MRI 2025!

The biannual conference, running this year from November 9th-11th in Berlin, Germany, brings together leading experts in neuromuscular imaging and disease to exchange ideas and discuss the latest research in the field.
This year’s focus on muscle MRI as an outcome measure in clinical trials underscores the growing importance of MRI-based measures in advancing neuromuscular disease (NMD) research and therapeutic development.

As the global leader in quantitative MRI analysis within neuromuscular disease trials, we're proud to contribute to the conversation at this year’s conference. AMRA’s own Markus Karlsson, PhD will be joining the roundtable session, “Unmet Need for Pharmaceutical Trials,” as an expert discussant to provide AMRA’s perspective on how imaging approaches can continue to be used to improve clinical trial outcomes in NMDs.

Will you be at MYO-MRI 2025? We’d love to connect and discuss how AMRA’s advanced MRI-based biomarkers can help enhance sensitivity and reproducibility in your neuromuscular trials.

Reach out to our Chief Globalization Officer, Leanna Kellerman, or to Markus Karlsson who will both be on-site in Berlin for MYO-MRI 2025 to schedule a time to meet – or send us a note at info@amramedical.com.

28/10/2025

Come Chat with AMRA at BIO-EUROPE 2025!

AMRA is excited to be joining industry leaders, innovators, and partners at the BIO-EUROPE 2025 conference in Vienna, taking place November 3–5! BIO-EUROPE is one of the world’s premier life science partnering events, bringing together stakeholders from all parts of the industry to build relationships that help drive life sciences organizations and bioinnovation forward.

Our Chief Globalization Officer, Leanna Kellerman, will be on-site to connect and discuss how AMRA’s advanced MRI-based fat distribution and muscle composition biomarker solutions can help advance your science and clinical research efforts.

If you’re attending BIO-EUROPE, we’d love to meet you in Vienna! Reach out to Leanna Kellerman or to info@amramedical.com to get in touch with us ahead of the event. We can’t wait to see you there!

22/10/2025

Meet AMRA at The Obesity Society’s ObesityWeek® 2025, taking place November 4–7 in Atlanta, GA!

This year’s focus — “Obesity as a Chronic Disease” — highlights the importance of long-term, evidence-based strategies for prevention, care, and management.

As the gold standard for fat distribution and muscle composition analytics, AMRA is looking forward to holding discussions around obesity as it emerges as a chronic condition at this year’s conference, and learning more about how we can continue to utilize our deep expertise and our MRI-based measures to help advance research and clinical care.

Will you be at ObesityWeek® 2025? Get in touch with our team members who will be on site in Atlanta, Conrad Maurais, and Olof Dahlqvist Leinhard, to connect and learn more about how AMRA can help you drive progress in obesity treatment and care forward! You can reach us at info@amramedical.com.

13/10/2025

We’re honored to be featured in Corren following our inclusion in TIME Magazine’s list of the world’s top health tech companies for 2025!

A big thank you to our amazing team and partners who make this possible. Together, we’re transforming how the world understands and treats obesity. 💪🌍

Med sina mediciner mot övervikt har bolag som Novo Nordisk och Eli Lilly blivit omtalade världen över. I Linköping finns ett företag som varit med i...

09/10/2025

AMRA Medical at the Nordic Network SLD 2025 Meeting!

This week, AMRA Medical’s very own Mikael Forsgren, PhD, and Olof Dahlqvist Leinhard, PhD, are attending the Nordic Network in Steatotic Liver Disease (SLD) Meeting, taking place here at home on the 9th and 10th of October in Stockholm, Sweden!

The by-invitation initiative brings together leading experts with a range of backgrounds from across the Nordic region to foster collaboration, strengthen research networks, and advance healthcare and public engagement of steatotic liver disease.

As a major contributor to various efforts in liver and metabolic disease research, AMRA is proud to add to this growing dialogue on liver health at this week’s meeting. If you’ll be at the Nordic SLD Meeting and want to connect with Mikael or Olof – send us a note here or reach out to info@amramedical.com!

25/09/2025

Catch Up With AMRA at The 2025 Global CMT Research Foundation This Week!

We’re excited to be in attendance at the 2025 edition of the Global Charcot-Marie-Tooth (CMT) Research Convention, which runs until September 27th in Cambridge, Massachusetts!

Our own Conrad Maurais will be on-site to share insights about AMRA’s MRI-based technology and solutions in clinical research. If you’re interested in getting in touch with Conrad, reach out via info@amramedical.com.

Hosted by the CMT Research Foundation, the event brings together patients, scientists, biopharma leaders, investors, and regulators with a shared mission: advancing treatments for Charcot-Marie-Tooth disease. CMT 2025 will feature scientific sessions designed for researchers, investors, and industry experts working to deepen understanding of CMT and drive progress toward a cure. You can learn more about CMT 2025 here: https://cmtconvention.cmtrf.org/

We hope to see you there!

19/09/2025

New AMRA Research Shared at EASD 2025 Demonstrates That Muscle Wasting is Accelerated in Individuals with Type 2 Diabetes

The study, “Muscle wasting and type 2 diabetes: Normative data for muscle composition changes with ageing,” presented yesterday by Dr. Jennifer Linge during the conference's Short Oral presentation session, found that individuals with T2D experience a more rapid decline in muscle volume and an increase in muscle fat infiltration with aging compared to their healthy counterparts.

Learn more about how we’re using our mission to advance metabolic disease research and beyond by reaching out on LinkedIn or by contacting us at info@amramedical.com.

18/09/2025

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’

We are proud to share our inclusion in the inaugural World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista!

The selection, which comes just one week after celebrating our 15 years of progress and innovation within the body composition space, highlights our long-standing commitment to becoming a global leader in health informatics by pioneering fat and muscle analysis with proprietary MRI-based technologies.

AMRA has received a “Very High” ranking within the Diagnostics Sector of the list, reflecting the company’s commitment to scientific rigor, innovation, and a mounting global reputation.

Read more about AMRA’s selection to the list and full rankings here: https://time.com/7318020/worlds-top-healthtech-companies-2025/

We’re thrilled to share this exciting news with our network, and cannot wait for future achievements!

17/09/2025

The AMRA team is at - diving into the latest updates in the diabetes field. If you are here and want to meet with us - connect via info@amramedical.com or reach out directly to (from the right) Dr. Jennifer Linge, Nicklas Weman, Leanna Kellerman, Mikaela Odlander or Marie Börjesson.

Don’t miss Jennifer Linge's presentation tomorrow: “Muscle wasting and type 2 diabetes: Normative data for muscle composition changes with ageing,” at 14:00–15:00 (Short Oral F session).

09/07/2025

AMRA Headlines as Lead Partner @ The 3rd Annual Obesity and Weight Loss Drug Development Summit!

📅 SAVE THE DATE: July 14th - 16th, 2025 | Boston, MA

We are absolutely thrilled to join the 3rd Annual Obesity and Weight Loss Drug Development Summit as the 2025 Lead Partner! Join our CEO, Dr. Olof Dahlqvist Leinhard, as he discusses how transformative MRI-based body composition methods and AMRA’s unique biomarkers are redefining obesity drug trials:

🔬 "MRI-based Body Composition Reimagined: Building a New Foundation for Treatment Differentiation Beyond Weight Loss"
👨🏻‍🔬 Olof Dahlqvist Leinhard, PhD
🗓 July 15th, 9:00am

The Obesity and Weight Loss Drug Development Summit, entering its third year, gathers the leading pharma, biotech, clinical, and academic thought partners to chart the next wave of obesity therapeutics—from navigating new guidelines to advancing personalized, muscle-preserving and side-effect-sparing treatment strategies.

As the obesity treatment landscape has evolved significantly over the past few years with the advent of GLP-1-based therapies, AMRA has been involved in many high-profile studies that evaluate the effects of anti-obesity medications on fat distribution and muscle composition. AMRA’s novel body fat and muscle volume z-score biomarkers uncover and help quantify these deeper-than-surface-level changes in body composition, and deepening insights within obesity treatment differentiation.

Powered by AMRAⓇ Researcher, the body fat and muscle volume z-score biomarkers provide reproducible and reliable measures of fat distribution and muscle composition, determining how far each participant deviates from the expected fat or muscle volume for someone with their s*x and body mass index.

This new, s*x-, height-, weight-, and BMI-invariant approach to quantifying body composition has made strides in helping drug manufacturers retrieve better insights during their trials – particularly by enabling a shift in focus while designing trials – from simply targeting great weight reduction to achieving a high-quality weight reduction. Providing measures, such as the z-scores, that assist manufacturers in developing a more nuanced understanding of how their interventions might affect body composition beyond simple weight loss adds a new tool to allow them to differentiate their products in the fast-moving, ever-changing GLP-1 landscape of today.

We are proud to be this year’s Summit Lead Partner, a testament to our commitment to doing our part in shaping the future of the obesity and weight loss drug development landscape. We can’t wait to see you there!

📥 Download the event guide here: https://shorturl.at/lSq18

Interested in MRI-based muscle assessment and its use in determining the relationship between drug-induced weight reduction and muscle health? Read more: https://shorturl.at/8iuEQ

25/06/2025

Do you want to be part of a dedicated, professional, and visionary team – shaping the future of precision health?

🚀 We are hiring! As Scientific Writer, you will be an integral part of AMRA’s Science team, contributing to the development of scientific publications, abstracts, and communication materials that highlight the company’s unique technology and research.

You’ll collaborate closely with clinical scientists, statisticians, and the BD/marketing team to create impactful, high-quality content that supports both academic credibility and commercial growth.

👉 Apply here: https://peaksearch.positionett.se/assignment.php?id=1284